Prognostic Value of Ambulatory Blood Pressure Load in Pediatric CKD

Jason Lee,1,2 Charles E. McCulloch,3 Joseph T. Flynn,4 Joshua Samuels,5 Bradley A. Warady,6 Susan L. Furth,7 Divya Seth,1,8,9 Barbara A. Grimes,1 Mark M. Mitsnefes1,10 and Elaine Ku1,2,3,8,9

Abstract

Background and objectives Elevated BP load is part of the criteria for ambulatory hypertension in pediatric but not adult guidelines. Our objectives were to determine the prevalence of isolated BP load elevation and associated risk with adverse outcomes in children with CKD, and to ascertain whether BP load offers risk discrimination independently or in conjunction with mean ambulatory BPs.

Design, setting, participants, & measurements We studied 533 children in the CKD in Children (CKiD) Study to determine the prevalence of normotension, isolated BP load elevation (≥25% of all readings elevated but mean BP normal), and ambulatory hypertension. We examined the association between these categories of BP control and adverse outcomes (left ventricular hypertrophy [LVH] or ESKD). We used c-statistics to determine risk discrimination for outcomes by BP load used either independently or in conjunction with other BP parameters.

Results Overall, 23% of the cohort had isolated BP load elevation, but isolated BP load elevation was not statistically significantly associated with LVH in cross-section (odds ratio, 1.8; 95% CI, 0.8 to 4.2) or time to ESKD (hazard ratio, 1.2; 95% CI, 0.7 to 2.0). In unadjusted cross-sectional analysis, every 10% higher systolic BP load was associated with 1.1-times higher odds of LVH (95% CI, 0.9 to 1.3), but discrimination for LVH was poor (c=0.61). In unadjusted longitudinal analysis, every 10% higher systolic BP load was associated with a 1.2-times higher risk of ESKD (95% CI, 1.1 to 1.2), but discrimination for ESKD was also poor (c=0.60). After accounting for mean systolic BP, systolic BP load was not statistically significantly associated with either LVH or ESKD. Findings were similar with diastolic BP load.

Conclusions BP load does not provide additive value in discriminating outcomes when used independently or in conjunction with mean systolic BP in children with CKD.


Introduction

Ambulatory BP monitoring is regarded as the gold standard for the evaluation, diagnosis, and confirmation of hypertension in children (1,2). The major advantage of ambulatory BP monitoring is its ability to provide repeated BP measurements over 24 hours outside of a provider’s office (1–3). Ambulatory BP monitoring also provides an assessment of BP load (percentage of readings above the upper limit of normal in a 24-hour period) (4,5). However, the inclusion of BP load as a criterion for the diagnosis of ambulatory hypertension is not uniform across all existing ambulatory BP monitoring guidelines. For example, BP load is part of the definition for ambulatory hypertension in the 2014 American Heart Association (AHA) pediatric ambulatory BP monitoring guidelines and mentioned in the American Academy of Pediatrics BP guidelines for children (2,3,6). In contrast, BP load is not included in the European guidelines for children or in the adult AHA 2017 guidelines as a criterion for the diagnosis of ambulatory hypertension (1,6–8).

Clinically, incorporating BP load into the routine assessment of hypertension can lead to confusion for practitioners, because patients can have a normal mean ambulatory BP but an elevated BP load (defined by guidelines as having ≥25% of ambulatory readings during a 24-hour period above the 95th percentile for sex and height for children) (1,6,9). When these situations occur, it is unclear whether to classify the patient as hypertensive (elevated ambulatory BP and BP load) or not (normal ambulatory BP and BP load).

The prevalence of children with an “uncategorized” BP status (e.g., isolated elevations in BP load) is unknown given the lack of large centralized ambulatory BP monitoring registries. It is also unclear whether BP load is prognostically important: many observational studies in both the adult and pediatric literature have found elevated BP load to be independently associated with target organ damage, but not all of these studies address whether BP load is prognostic of target organ damage after accounting for other ambulatory BP parameters (e.g., absolute mean BPs) (10–15).
Our objective was to determine the prevalence of normotension, isolated BP load elevation (defined as elevated systolic BP or diastolic BP load but normal mean systolic BP and diastolic BPs), and hypertension, and their association with left ventricular hypertrophy (LVH) or ESKD in children with CKD. We also investigated whether elevated BP load provides either independent or additive prognostic value (when used in conjunction with mean awake or sleep ambulatory BPs) for risk of LVH (in cross-sectional and longitudinal analysis) or ESKD (in longitudinal analysis) in the CKD in Children (CKiD) Study.

Materials and Methods

Study Population

Details of the CKiD Study have been previously described (16). Briefly, CKiD is an ongoing prospective multicenter cohort study of children between the ages of 1 and 16 years with an eGFR of between 30 and 90 ml/min per 1.73 m² (16,17). Outcomes of interest in the CKiD Study include the progression of kidney disease, cardiovascular disease, growth, and cognition. We included 533 participants who had a baseline visit with echocardiogram and ambulatory BP monitoring, and excluded a total of 247 children who had either missing echocardiogram (n=69) or ambulatory BP monitoring (n=178), a subset of whom were under the age of 5 when ambulatory BP monitoring would not be routinely performed (9). Informed consent was obtained from study participants across all CKiD sites. De-identified data were derived from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository and administratively censored as of July 2014. The University of California San Francisco Institutional Review Board considers this study not human subjects research.

Predictors of Interest

Ambulatory Blood Pressure Monitoring. Ambulatory BP monitoring was performed during the CKiD Study using a SpaceLabs 90217 monitor (SpaceLabs Healthcare, Snoqualmie, WA), with BPs taken every 20 minutes over 24 hours and centrally analyzed as described previously (9,18). All ambulatory BP monitoring performed as part of the baseline assessment (and typically on the same day as echocardiogram) were included for analysis. We used awake or asleep ambulatory BP readings as separate predictors of interest. We converted all ambulatory BP measurements into BP indices as in prior CKiD studies using a 95th percentile threshold to define ambulatory hypertension, such that an index of 1 would represent a BP that was exactly at the 95th percentile for sex and height (9,19–21). Similar to prior CKiD studies, we used European normative data from Soergel and colleagues to determine thresholds for ambulatory BP (18,20,21).

Blood Pressure Parameters of Interest. We were interested in comparing the strength of the association between systolic BP and diastolic BP load with outcomes of interest, both as independent and additive predictors (e.g., used jointly with other ambulatory BP monitoring parameters such as awake and asleep mean BP index). Systolic BP and diastolic BP load were treated as continuous predictors of interest ranging from 0% to 100% and assessed separately during awake and sleep periods as in prior CKiD studies (9,18). We considered a BP load ≥25% to be elevated (as defined in pediatric ambulatory BP monitoring guidelines and in prior CKiD studies) (1,9). In sensitivity analysis, we also defined systolic BP load as a categorical predictor ranging from 0% to <25%, 25% to <50%, and 50% to 100%. Of note, we focused primarily on systolic BP and its association with adverse outcomes throughout this study (except when classifying patients as hypertensive or normotensive, in which case both systolic BP and diastolic BP were considered), given that prior studies have demonstrated the greater prognostic importance of systolic BPs, as opposed to diastolic BPs in their association with outcomes in children with CKD (18,19,22).

Outcomes of Interest

Left Ventricular Hypertrophy. Echocardiograms and 24-hour ambulatory BP monitoring were performed every 2 years in the CKiD Study after baseline determination and were included in our primary analysis. M-mode and Doppler echocardiograms were performed by trained technologists using a standardized protocol at CKiD sites (18). We defined LVH using the same definitions used in prior CKiD studies, which is a left ventricular mass index ≥95th percentile for children and adolescents (18). The median time difference between 24-hour ambulatory BP monitoring and echocardiogram performance was 0 days (interquartile range [IQR], 0–0) at baseline. Our primary analysis of LVH focused on data collected at baseline; however, in secondary analysis, we examined the association between various BP parameters and the presence or absence of LVH at the baseline and the 2-year follow-up visit.

Long-Term ESKD Ascertainment. Ascertainment of ESKD onset (defined as the first date of dialysis or transplantation) was performed at annual CKiD visits, by phone follow-up, or by the provision of data from providers. Patients were administratively censored if they were alive as of July 2014 and had not yet developed ESKD, or if they were lost to follow-up at the time of the last known study visit.

Statistical Analyses

Isolated Blood Pressure Load Elevation and Its Association with Outcomes of Interest. First, we categorized the BP status of each individual in the cohort by ambulatory BP monitoring as either normotensive (both normal systolic BP and diastolic BP awake and asleep indices [i.e., index <1.0] and normal awake and asleep BP load, respectively), hypertensive (elevated systolic BP or diastolic BP awake or asleep indices [i.e., index ≥1.0], regardless of BP load), versus isolated BP load elevation (normal systolic BP and diastolic BP awake and asleep indices [i.e., index <1.0], but either elevated awake or asleep systolic BP or diastolic BP load ≥25%). We then compared the characteristics of these subgroups using chi-squared or Kruskal-Wallis tests as appropriate. Next, we examined the association between BP status (normotensive, isolated BP load elevation, or hypertensive) and LVH at baseline using logistic models (cross-sectional analysis) and ESKD in Cox models (longitudinal analysis) using both unadjusted and adjusted analyses.
For longitudinal ESKD analyses, time to event was determined by starting from the date of the visit when the echocardiogram was performed (which was also typically the date of performance of ambulatory BP monitoring) (23). In adjusted analyses, we accounted for age, sex, race (white, black, or other), cause of CKD (glomerular or nonglomerular), body mass index z-score, eGFR by the bedside Schwartz equation, urine protein-creatinine ratio, and use of antihypertensive medications (all ascertainment at the visit where echocardiogram was obtained) as covariates.

**Prognostic Value of Blood Pressure Load.** We first included awake or asleep systolic BP or diastolic BP load as independent predictors of baseline LVH (using logistic models) and ESKD (using Cox models) in unadjusted analyses.

In secondary analysis, we examined whether systolic BP load and ambulatory systolic BP’s predicted LVH longitudinally (at baseline and at the 2-year follow-up visit) using mixed-effects logistic regression models incorporating repeated measures of BP parameters and LVH.

We considered these unadjusted models our primary analysis because we were interested in comparisons of different BP parameters in the same CKiD participant as predictors of outcomes. To provide formal tests of the ability of each BP metric to discriminate risk of outcomes, c-statistics were determined for each logistic or Cox model. In logistic models, the c-statistics were determined as the area under the receiver operator curve. In Cox models, Harrell’s c-statistics were used. C-statistics, or concordance statistics, provide a measure of risk discrimination (i.e., the probability that a person with the event has a higher predicted probability than a person without the event). Confidence intervals for c-statistics and their differences were determined via a bootstrapping technique (using 500 repetitions) to evaluate the fit of each Cox model. We repeated our models in adjusted analyses, accounting for the same covariates as described above and determined the c-statistics for these adjusted models.

We then performed separate analyses using awake or asleep mean BP indices as independent predictors of the outcomes of interest in unadjusted and adjusted analyses, and determined the c-statistics for these models.

Finally, we used nested models to determine whether BP load provided additive prognostic value when used in conjunction with awake or asleep BP indices. In nested models, we included both awake BP indices and awake BP load in the same logistic or Cox model and repeated our unadjusted and adjusted analyses. We repeated these models for sleep parameters separately. We used the c-statistic for systolic BP (or diastolic BP) load as the reference group when determining whether differences in c-statistic between unadjusted or nested models (e.g., awake systolic BP load versus awake mean systolic BP index) were statistically significant.

In sensitivity analysis, we repeated all analyses above using awake or asleep systolic BP load as a categorical (rather than continuous) predictor for both outcomes of interest, and determined model discrimination.

Stata 14 (StataCorp LLC, College Station, TX) was used for the performance of all statistical analyses and verified by a separate analyst. P<0.05 was considered statistically significant for all analyses.

**Results**

Baseline characteristics of the 533 CKiD Study participants included for analysis are shown in Table 1. The median age was 13 (IQR, 9–16) years, 61% were boys, and the median eGFR was 51 (IQR, 34–66) ml/min per 1.73 m². We found that approximately one-quarter of the cohort had isolated BP (either systolic or diastolic) load elevation. Approximately one-third of the participants had elevated mean systolic BP or diastolic BP indices that met the criteria for ambulatory hypertension, and 40% were normotensive (Table 1). The prevalence of LVH was statistically significantly higher in children with hypertension compared with those with normotension (17% versus 7%, P=0.001) but did not differ between those with isolated BP load elevation and normotension (12% versus 7%, P=0.08). The mean awake systolic BP index (and SD) in this cohort was 0.91 (SD=0.08) and mean asleep systolic BP index was 0.92 (SD=0.10).

**Ambulatory Blood Pressure Status and Risk of Adverse Outcomes**

Approximately 12% of the cohort (n=62) had LVH on their baseline echocardiogram (Table 1). Among the 224 participants with available echocardiogram and ambulatory BP data at the 2-year visit, 11% (n=25) had LVH at follow-up. During a mean follow-up of 3.5 years (SD=2.5), 23% (n=125) of participants developed ESKD. In both unadjusted and adjusted analysis, isolated BP load elevation was not statistically significantly associated with the odds of LVH at baseline or time to ESKD (Table 2) compared with normotension. In contrast, hypertension was strongly associated with LVH and ESKD (Table 2), although the association with ESKD was attenuated in adjusted models.

**Blood Pressure Load and Left Ventricular Hypertrophy**

When we examined awake and asleep systolic BP load as a continuous variable, neither awake nor asleep systolic BP load were statistically significantly associated with the odds of LVH in unadjusted analyses (Table 3). Similar findings were noted in fully adjusted models and nested models (incorporating other ambulatory BP parameters), as shown in Table 3.

The c-statistics for models including awake or asleep systolic BP load as the sole predictor of LVH were low (c=0.61 and 0.62, respectively; Table 3). The c-statistic for models including both awake systolic BP load and awake systolic BP index was not improved in comparison with the model with awake systolic BP load as a sole predictor (c=0.62). Similar findings were noted with nested models of asleep systolic BP load and asleep systolic BP index. In fully adjusted models, the c-statistics for all models were improved, but systolic BP load did not improve risk discrimination when used in conjunction with mean BP parameters (Table 3).

When we performed analyses by diastolic BP, we found that awake and asleep diastolic BP load were associated with the odds of LVH as sole predictors, although model discrimination remained low (Supplemental Table 1A). When awake or asleep diastolic BP indices were added to diastolic BP load, diastolic BP load was no
longer statistically significantly associated with the odds of LVH.

When we repeated our models using repeated measures of BP load and other BP parameters to predict LVH during the longitudinal follow-up at 2 years using mixed logistic models, we found that systolic BP load did not consistently provide better risk discrimination compared with systolic BP index (Supplemental Table 2). Overall, the c-statistic remained low for all BP parameters. In adjusted models, systolic BP load also did not provide statistically significantly better risk discrimination, compared with the systolic BP index, consistently for risk of LVH.

In sensitivity analysis, when we repeated our models using awake or asleep systolic BP load as a categorical predictor, we found that results were similar to our primary analysis for the outcome of LVH (Supplemental Table 3A).

### Longitudinal Analysis of ESKD Risk

Awake and asleep systolic BP load were both independently associated with the risk of ESKD in unadjusted analysis.

---

**Table 1. Characteristics of the participants in CKiD by ambulatory BP status**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall Cohort</th>
<th>Normotensiona</th>
<th>Isolated BP Load Elevationb</th>
<th>Hypertensionc</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (%)</td>
<td>533 (100)</td>
<td>213 (40)</td>
<td>123 (23)</td>
<td>197 (37)</td>
</tr>
<tr>
<td>Median age, yr (IQR)</td>
<td>13 (9, 16)</td>
<td>13 (10, 15)</td>
<td>13 (9, 16)</td>
<td>12 (9, 16)</td>
</tr>
<tr>
<td>Maleb</td>
<td>326 (61)</td>
<td>123 (58)</td>
<td>85 (69)</td>
<td>118 (60)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>366 (69)</td>
<td>167 (78)</td>
<td>84 (69)</td>
<td>115 (58)</td>
</tr>
<tr>
<td>Black</td>
<td>76 (14)</td>
<td>15 (7)</td>
<td>20 (16)</td>
<td>41 (21)</td>
</tr>
<tr>
<td>Other</td>
<td>91 (17)</td>
<td>31 (15)</td>
<td>19 (15)</td>
<td>41 (21)</td>
</tr>
<tr>
<td><strong>Cause of CKD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glomerular</td>
<td>142 (27)</td>
<td>63 (30)</td>
<td>30 (24)</td>
<td>49 (25)</td>
</tr>
<tr>
<td>Nonglomerular</td>
<td>391 (73)</td>
<td>150 (70)</td>
<td>93 (76)</td>
<td>148 (75)</td>
</tr>
<tr>
<td><strong>Age- and sex-adjusted BMI z-score (IQR)d</strong></td>
<td>0.3 (−0.4, 1.3)</td>
<td>0.3 (−0.5, 1.4)</td>
<td>0.6 (−0.1, 1.5)</td>
<td>0.2 (−0.5, 0.9)</td>
</tr>
<tr>
<td>Median eGFR in ml/min per 1.73 m² by bedside Schwart (IQR)</td>
<td>51 (34, 66)</td>
<td>54 (34, 68)</td>
<td>51 (39, 64)</td>
<td>49 (31, 64)</td>
</tr>
<tr>
<td>Hemoglobin, g/dl (IQR)</td>
<td>13 (12, 14)</td>
<td>13 (12, 14)</td>
<td>13 (12, 14)</td>
<td>13 (12, 14)</td>
</tr>
<tr>
<td>Serum albumin, g/dl (IQR)</td>
<td>4.3 (4, 4.6)</td>
<td>4.4 (4, 4.6)</td>
<td>4.3 (4, 4.6)</td>
<td>4.3 (4, 4.6)</td>
</tr>
<tr>
<td>Left ventricular hypertrophy at baselined</td>
<td>0.88 ± 0.10</td>
<td>0.84 ± 0.08</td>
<td>0.88 ± 0.09</td>
<td>0.93 ± 0.10</td>
</tr>
<tr>
<td>Clinic systolic BP indexd,e</td>
<td>0.82 ± 0.14</td>
<td>0.77 ± 0.12</td>
<td>0.80 ± 0.12</td>
<td>0.89 ± 0.15</td>
</tr>
<tr>
<td>Clinic diastolic BP indexd,e</td>
<td>0.91 ± 0.08</td>
<td>0.86 ± 0.06</td>
<td>0.91 ± 0.05</td>
<td>0.98 ± 0.07</td>
</tr>
<tr>
<td>Awake systolic BP indexd</td>
<td>0.88 ± 0.10</td>
<td>0.81 ± 0.07</td>
<td>0.88 ± 0.06</td>
<td>0.96 ± 0.10</td>
</tr>
<tr>
<td>Awake diastolic BP indexd</td>
<td>13 (3, 33)</td>
<td>3 (0, 9)</td>
<td>14 (3, 26)</td>
<td>40 (19, 59)</td>
</tr>
<tr>
<td>Awake diastolic BP loadd</td>
<td>15 (3, 51)</td>
<td>6 (2, 10)</td>
<td>16 (7, 27)</td>
<td>36 (21, 55)</td>
</tr>
<tr>
<td>Asleep systolic BP indexd</td>
<td>0.92 ± 0.10</td>
<td>0.85 ± 0.06</td>
<td>0.91 ± 0.04</td>
<td>1.00 ± 0.07</td>
</tr>
<tr>
<td>Asleep diastolic BP indexd</td>
<td>0.92 ± 0.13</td>
<td>0.81 ± 0.07</td>
<td>0.92 ± 0.06</td>
<td>1.03 ± 0.11</td>
</tr>
<tr>
<td>Asleep systolic BP loadd</td>
<td>14 (0, 39)</td>
<td>0 (0, 6)</td>
<td>15 (5, 28)</td>
<td>50 (28, 75)</td>
</tr>
<tr>
<td>Asleep diastolic BP loadd</td>
<td>21 (6, 47)</td>
<td>5 (0, 12)</td>
<td>28 (19, 36)</td>
<td>56 (33, 75)</td>
</tr>
<tr>
<td>Antihypertensive medication use</td>
<td>362 (68)</td>
<td>152 (71)</td>
<td>77 (63)</td>
<td>133 (68)</td>
</tr>
<tr>
<td><strong>Awake systolic BP loadd</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0% to &lt;25%</td>
<td>366 (68)</td>
<td>213 (100)</td>
<td>90 (73)</td>
<td>63 (32)</td>
</tr>
<tr>
<td>25% to &lt;50%</td>
<td>89 (17)</td>
<td>0 (0)</td>
<td>33 (27)</td>
<td>56 (28)</td>
</tr>
<tr>
<td>50%–100%</td>
<td>78 (15)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>78 (40)</td>
</tr>
<tr>
<td><strong>Asleep systolic BP loadd</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0% to &lt;25%</td>
<td>340 (64)</td>
<td>213 (100)</td>
<td>86 (70)</td>
<td>41 (21)</td>
</tr>
<tr>
<td>25% to &lt;50%</td>
<td>89 (17)</td>
<td>0 (0)</td>
<td>35 (28)</td>
<td>54 (27)</td>
</tr>
<tr>
<td>50%–100%</td>
<td>104 (19)</td>
<td>0 (0)</td>
<td>2 (2)</td>
<td>102 (52)</td>
</tr>
<tr>
<td><strong>Awake diastolic BP loadd</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0% to &lt;25%</td>
<td>365 (69)</td>
<td>213 (100)</td>
<td>86 (70)</td>
<td>66 (34)</td>
</tr>
<tr>
<td>25% to &lt;50%</td>
<td>102 (19)</td>
<td>0 (0)</td>
<td>35 (28)</td>
<td>67 (34)</td>
</tr>
<tr>
<td>50%–100%</td>
<td>66 (12)</td>
<td>0 (0)</td>
<td>2 (2)</td>
<td>64 (32)</td>
</tr>
<tr>
<td><strong>Asleep diastolic BP loadd</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0% to &lt;25%</td>
<td>284 (54)</td>
<td>213 (0)</td>
<td>44 (36)</td>
<td>27 (14)</td>
</tr>
<tr>
<td>25% to &lt;50%</td>
<td>126 (24)</td>
<td>0 (0)</td>
<td>78 (63)</td>
<td>48 (24)</td>
</tr>
<tr>
<td>50%–100%</td>
<td>123 (23)</td>
<td>0 (0)</td>
<td>1 (1)</td>
<td>122 (62)</td>
</tr>
</tbody>
</table>

Values are means ±SD or N (%), unless otherwise specified. IQR, interquartile range; BMI, body mass index.

aNormotension was defined as awake and asleep systolic BP and diastolic BP index <1.0 (e.g., mean ambulatory BP <95th percentile for sex and height), as well as awake and asleep systolic BP or diastolic BP load <25%.

bIsolated BP load elevation was defined as awake and asleep systolic BP or diastolic BP index <1.0, with awake or asleep systolic BP or diastolic BP load ≥25%.

cHypertension was defined as ambulatory awake or sleep systolic BP or diastolic BP index ≥1.0, regardless of BP load.

dStatistically significantly different by BP control category (P<0.05).

eClinic BP readings were indexed to the 95th percentile thresholds for age, sex, and height; an index of 1 would represent a clinic BP that was exactly at the 95th percentile for age, sex, and height derived from the National High BP Education Program Fourth Report as in prior CKiD studies.
with the risk of ESKD as sole predictors, although model
Table 1B). Awake and asleep diastolic BP load were associated
with mean BP indices, respectively. Provide additive prognostic value to either awake or asleep
but awake or asleep systolic BP load did not appear to
improved and similar across all models (c
(95% CI). In fully adjusted models, the c-statistics were
asleep systolic BP load for the risk of ESKD was also low
dependently or as an additive prognostic risk factor (Table 4).
In sensitivity analysis, when we repeated our models using
awake or asleep systolic BP load as a categorical predictor,
results were similar in both unadjusted and adjusted analyses
for hazard of ESKD (Supplemental Table 3B).

Discussion
BP load has been considered a predictor of target organ
damage due to its reflection of the overall burden of
elevated BPs during 24-hour ambulatory BP monitoring
(4,5). However, whether BP load offers prognostic information regarding the risk of target organ damage in a
manner that is independent of mean ambulatory BP in
children with CKD is uncertain (10,12–14,24,25).

(4). However, after accounting for awake or asleep
mean systolic BP indices by ambulatory BP monitoring, awake
and asleep systolic BP load were no longer statistically
significantly associated with the risk of ESKD. In fully adjusted
models, neither awake nor asleep systolic BP load were
statistically significantly associated with risk of ESKD in-
dependently or as an additive prognostic risk factor (Table 4),
Overall, the c-statistic for models including awake or
asleep systolic BP load for the risk of ESKD was also low
(Table 4). In fully adjusted models, the c-statistics were
improved and similar across all models (c=0.88, Table 4),
but awake or asleep systolic BP load did not appear to
provide additive prognostic value to either awake or asleep
mean BP indices, respectively.
When we performed analyses by diastolic BP, similar
findings were noted for the outcome of ESKD (Supplemental
Table 1B). Awake and asleep diastolic BP load were associated
with the risk of ESKD as sole predictors, although model
discrimination remained low. When awake or asleep
diastolic BP indices were added to diastolic BP load, diastolic
BP load was no longer statistically significantly associated
with the risk of ESKD.

Table 3. Association between systolic BP parameters and LVH (in cross-section) in unadjusted and adjusted analyses along with model discrimination

<table>
<thead>
<tr>
<th>Systolic BP Metrics (n=533)</th>
<th>Unadjusted OR (95% CI)</th>
<th>Unadjusted c-Statistic (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
<th>Adjusted c-Statistic (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awake systolic BP load (every 10% higher)</td>
<td>1.1 (1.0 to 1.3)</td>
<td>0.61 (0.53 to 0.68)</td>
<td>1.1 (1.0 to 1.3)</td>
<td>0.77 (0.72 to 0.83)</td>
</tr>
<tr>
<td>Awake systolic BP index (every 0.1 higher)</td>
<td>1.7 (1.2 to 2.3)</td>
<td>0.62 (0.55 to 0.69)</td>
<td>1.6 (1.1 to 2.3)</td>
<td>0.78 (0.73 to 0.83)</td>
</tr>
<tr>
<td>Awake systolic BP load plus awake systolic BP index</td>
<td>2.4 (1.0 to 5.6)</td>
<td>0.62 (0.55 to 0.69)</td>
<td>2.7 (1.0 to 7.2)</td>
<td>0.78 (0.73 to 0.84)</td>
</tr>
<tr>
<td>Asleep systolic BP load (every 10% higher)</td>
<td>1.1 (1.0 to 1.2)</td>
<td>0.62 (0.55 to 0.69)</td>
<td>1.1 (1.0 to 1.2)</td>
<td>0.77 (0.72 to 0.83)</td>
</tr>
<tr>
<td>Asleep systolic BP index (every 0.1 higher)</td>
<td>1.5 (1.1 to 2.0)</td>
<td>0.63 (0.56 to 0.70)</td>
<td>1.5 (1.1 to 2.0)</td>
<td>0.78 (0.72 to 0.83)</td>
</tr>
<tr>
<td>Asleep systolic BP load plus asleep systolic BP index</td>
<td>0.9 (0.8 to 1.2)</td>
<td>0.63 (0.56 to 0.71)</td>
<td>0.9 (0.7 to 1.2)</td>
<td>0.78 (0.72 to 0.83)</td>
</tr>
</tbody>
</table>

LVH, left ventricular hypertrophy; OR, odds ratio.
1 OR for every 0.1 higher systolic BP index or 10% higher systolic BP load.
2 Adjusted for age, sex, race, cause of CKD, body mass index z-score, urine protein-creatinine ratio, antihypertensive use, and baseline eGFR (by bedside Schwartz), n=515 included due to missing covariates.
3 Reference group for awake or asleep c-statistic comparisons.

Table 2. Risk of LVH or ESKD by ambulatory BP status in unadjusted and adjusted analyses

<table>
<thead>
<tr>
<th>Ambulatory BP Classification (n=533)</th>
<th>LVH</th>
<th>ESKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Events (n=62)</td>
<td>Unadjusted OR (95% CI)</td>
<td>Adjusted OR (95% CI)</td>
</tr>
<tr>
<td>Normotension (n=213)</td>
<td>14</td>
<td>Reference</td>
</tr>
<tr>
<td>Isolated BP load elevation (n=123)</td>
<td>15</td>
<td>2.0 (0.9 to 4.2)</td>
</tr>
<tr>
<td>Ambulatory Hypertension (n=197)</td>
<td>33</td>
<td>2.9 (1.5 to 5.5)</td>
</tr>
</tbody>
</table>

Isolated BP load elevation was defined as awake and asleep systolic BP or diastolic BP index <1.0, with awake or sleep BP load ≥25%.
Ambulatory hypertension was defined as awake or asleep systolic BP or diastolic BP index ≥1.0, regardless of BP load.

Table 2. Risk of LVH or ESKD by ambulatory BP status in unadjusted and adjusted analyses

<table>
<thead>
<tr>
<th>Ambulatory BP Classification (n=533)</th>
<th>LVH</th>
<th>ESKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Events (n=62)</td>
<td>Unadjusted OR (95% CI)</td>
<td>Adjusted OR (95% CI)</td>
</tr>
<tr>
<td>Normotension (n=213)</td>
<td>14</td>
<td>Reference</td>
</tr>
<tr>
<td>Isolated BP load elevation (n=123)</td>
<td>15</td>
<td>2.0 (0.9 to 4.2)</td>
</tr>
<tr>
<td>Ambulatory Hypertension (n=197)</td>
<td>33</td>
<td>2.9 (1.5 to 5.5)</td>
</tr>
</tbody>
</table>

LVH, left ventricular hypertrophy; OR, odds ratio.
1 Adjusted for age, sex, race, cause of CKD, body mass index z-score, urine protein-creatinine ratio, antihypertensive use, and baseline eGFR (by bedside Schwartz), n=515 included due to missing covariates.
2 Normotension was defined as awake and asleep systolic BP or diastolic BP index <1.0 (e.g., mean ambulatory BP <95th percentile for sex and height), with awake and asleep systolic BP or diastolic BP load <25%.
3 Isolated BP load elevation was defined as awake and asleep systolic BP or diastolic BP index <1.0, with awake or sleep BP load ≥25%.
4 Ambulatory hypertension was defined as awake or asleep systolic BP or diastolic BP index ≥1.0, regardless of BP load.

(Table 4).
association between isolated BP load elevation and risk of adverse outcomes has also been unclear in children with CKD. Yet, to date, BP load remains a part of the criteria for the diagnosis of ambulatory hypertension in most pediatric guidelines (1,6). In this study, we found that one-quarter of a cohort of children with CKD had an elevated BP load in the setting of normal mean ambulatory BP, although the majority of these children did not have a BP load of ≥50%. Although both awake and asleep BP loads were independently associated with the odds of LVH in unadjusted analyses, we found that after accounting for mean BP, BP load (as a continuous or categorical predictor) was no longer statistically significantly associated with outcomes and did not improve discrimination of the risk for LVH in cross-section or ESKD. We also did not find BP load to be associated with LVH in longitudinal follow-up at the 2-year visit after considering BP indices. Our study is one of the first to demonstrate that BP load was not independently associated with important clinical outcomes in a population of children with CKD.

Prior studies in the adult literature have evaluated the relationship between elevated BP load and target organ damage, but there is no clear consensus as to whether BP load offers additional information beyond that of mean ambulatory BPs (12,26–28). For example, Wang et al. (25) found a strong association between nighttime BP load and target organ damage independent of mean ambulatory BP values in a cohort of 1219 Chinese patients with CKD, but this analysis included mostly patients who were hospitalized. More recent literature has suggested that BP load may not provide additive information in predicting the risk of cardiovascular outcomes compared with mean absolute ambulatory BPs (13,14). The largest analysis to date to investigate whether BP load is independently prognostic of adverse outcomes was performed using data from the International Database of Ambulatory BP in relation to Cardiovascular Outcome (13). Although this study found that BP load and mean ambulatory BP were equally predictive of nonfatal and fatal CV events in a cohort of adults without significant CKD, BP load did not improve the discrimination of the risk for these cardiovascular outcomes.

Another study that evaluated 869 adults with untreated hypertension also found that higher tertiles of BP load were more predictive of target organ damage; however, when the investigators additionally adjusted for mean ambulatory BPs, these findings were no longer statistically significant (14).

Although there is consensus across pediatric ambulatory BP guidelines that ambulatory BP monitoring should be used for the confirmation of a diagnosis of hypertension, recommendations regarding the incorporation of BP load in the diagnostic approach for hypertension are inconsistent across different guidelines (6,7,29). Several pediatric studies have evaluated the association between BP load and target organ damage in children without CKD (10,11,15). One small study previously reported that BP load >50% in the presence of a 24-hour systolic BP index >1.0 was associated with LVH in a cohort of 37 children with untreated hypertension without CKD (15). Richey and colleagues found that every 25% higher systolic BP load was associated with higher odds of LVH in children, but these models did not account for mean ambulatory BP (15,30). Another study of children without CKD found that systolic BP load >25% was associated with higher carotid-intima media thickness and higher pulse-wave velocity, but not microalbuminuria or abnormal left ventricular mass index (11). Although our data are consistent with prior literature showing that BP load is associated with cardiovascular and kidney outcomes when used independently (and not accounting for mean ambulatory BPs), our study shows that BP load does not improve discrimination of these outcomes overall after accounting for mean ambulatory BPs. Isolated BP load elevation was associated with a tendency toward higher risk of LVH and ESKD compared with normotension, but this finding did not achieve statistical significance and it is unclear whether isolated BP load elevation would warrant treatment.

The strengths of our study include the availability of research-grade ambulatory BP monitoring data obtained from a well characterized cohort of children with CKD from large pediatric academic centers. We were able to examine the association between BP load and “hard outcomes”

### Table 4. Association between systolic BP parameters and ESKD in unadjusted and adjusted analyses along with model discrimination

<table>
<thead>
<tr>
<th>Systolic BP Metrics (n=533)</th>
<th>Unadjusted HR (95% CI)a</th>
<th>Unadjusted c-Statistic (95% CI)</th>
<th>Adjusted HR (95% CI)b</th>
<th>Adjusted c-Statistic (95% CI)b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awake systolic BP load (every 10% higher)</td>
<td>1.2 (1.1 to 1.2)</td>
<td>0.60 (0.54 to 0.65)c</td>
<td>1.1 (1.0 to 1.1)</td>
<td>0.89 (0.86 to 0.91)c</td>
</tr>
<tr>
<td>Awake systolic BP index (every 0.1 higher)</td>
<td>1.6 (1.3 to 1.9)</td>
<td>0.60 (0.55 to 0.65)</td>
<td>1.2 (1.0 to 1.5)</td>
<td>0.89 (0.86 to 0.91)</td>
</tr>
<tr>
<td>Awake systolic BP load plus awake systolic BP index</td>
<td>1.1 (1.0 to 1.3)</td>
<td>0.60 (0.55 to 0.67)</td>
<td>0.9 (0.7 to 1.0)</td>
<td>0.89 (0.85 to 0.91)</td>
</tr>
<tr>
<td>Asleep systolic BP load (every 10% higher)</td>
<td>1.1 (1.0 to 1.2)</td>
<td>0.58 (0.52 to 0.64)c</td>
<td>1.0 (1.0 to 1.0)</td>
<td>0.88 (0.85 to 0.91)c</td>
</tr>
<tr>
<td>Asleep systolic BP index (every 0.1 higher)</td>
<td>1.4 (1.1 to 1.6)</td>
<td>0.57 (0.52 to 0.63)</td>
<td>1.2 (1.0 to 1.4)</td>
<td>0.89 (0.85 to 0.91)</td>
</tr>
<tr>
<td>Asleep systolic BP load plus asleep systolic BP index</td>
<td>1.1 (0.9 to 1.2)</td>
<td>0.58 (0.52 to 0.64)</td>
<td>1.0 (0.8 to 1.1)</td>
<td>0.88 (0.85 to 0.91)</td>
</tr>
</tbody>
</table>

HR, hazard ratio. 
aHR reported for every 0.1 higher in systolic BP index or 10% higher systolic BP load. 
bAdjusted for age, sex, race, cause of CKD, body mass index z-score, duration of CKD, urine protein-creatinine ratio, serum albumin, hemoglobin, antihypertensive use, and baseline eGFR (by bedside Schwartz). 
cReference group for awake or asleep c-statistic comparisons.
representative of target organ damage, such as ESKD onset. We note a high number of ESKD events over a relatively short follow-up duration, which is a strength in CKiD. These rates are comparable to other pediatric cohorts such as the ESCAPE trial in European children with CKD (31). Both pediatric CKD cohorts demonstrate a higher event rate compared with outcomes from adult cohorts that may reflect differences in the etiology of CKD, of which glomerular disease may be more common in the pediatric population (32). Limitations to our study include the use of normative ambulatory BP monitoring data derived from a homogenous European population which may or may not apply to children of greater racial and ethnic diversity; however, no other ambulatory BP monitoring norms are currently available.

In conclusion, BP load does not appear to provide additional risk discrimination for cardiovascular or kidney outcomes above and beyond mean ambulatory BP indices obtained during ambulatory BP monitoring. Future studies are needed to confirm our findings in other pediatric populations with CKD and to determine whether BP load should still be incorporated into routine assessments of cardiovascular or kidney risk in children.

Acknowledgments

The data and samples from the CKiD Study reported here were supplied by the NIDDK Central Repositories. This manuscript does not necessarily reflect the opinions or views of the CKiD Study, the NIDDK Central Repositories, or the NIDDK. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH).

All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language, except as an abstract.

Disclosures

Dr. Ku reports a position on the pediatric advisory board at Reata Pharmaceuticals and received consultant fees from Tricida, outside of the submitted work. Dr. Flynn reports personal fees from Silvergate Pharmaceuticals, Ultragenyx, Vertex Pharmaceuticals, and royalties from Up To Date, all outside the published work. Dr. Furth, Dr. Mitsnefes, Dr. Grimes, Dr. Lee, Dr. McCulloch, Dr. Samuels, Ms. Seth, and Dr. Warady have nothing to disclose.

Funding

Dr. Lee is supported by T32 Ruth L. Kirschstein Institutional National Service award 2T32DK007219. Dr. Ku is supported by National Heart, Lung, and Blood Institute grant HL131023. Dr. Mitsnefes is supported by NIDDK grant DK090070. The CKiD Study was conducted by the CKiD Investigators and supported by NIDDK, with additional funding from the National Institute of Child Health and Human Development, the National Heart, Lung, and Blood Institute and NIDDK (U01-DK-66143, U01-DK-66174, U01-DK-082194, and U01-DK-66116). This publication was also supported by the National Center for Advanced Translational Sciences, NIH, through Clinical and Translational Science Institute, University of California San Francisco grant UL1 TR001872.

Supplemental Material

This article contains the following supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.10130819/-/DCSupplemental.

Supplemental Table 1A. Association between diastolic BP parameters and LVH (in cross-section) in unadjusted and adjusted analyses, along with model discrimination.

Supplemental Table 1B. Association between diastolic BP parameters and ESKD and in unadjusted and adjusted analyses, along with model discrimination.

Supplemental Table 2. Association between systolic BP parameters and LVH during 2-year follow-up, along with model discrimination.

Supplemental Table 3A. Association between systolic BP parameters and LVH in unadjusted and adjusted analyses using BP load as a categorical predictor along with model discrimination.

Supplemental Table 3B. Association between systolic BP parameters and ESKD in unadjusted and adjusted analyses using BP load as a categorical predictor along with model discrimination.

References


34. M.M.M. and E.K. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.

Received: August 28, 2019 Accepted: January 28, 2020

M.M.M. and E.K. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.

**AFFILIATIONS**

1Division of Pediatric Nephrology, University of California San Francisco, San Francisco, California; 2Department of Pediatrics, University of California San Francisco, San Francisco, California; 3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; 4Division of Nephrology, Department of Pediatrics, Seattle Children’s, Seattle, Washington; 5Division of Pediatric Nephrology, Department of Pediatrics, McGovern Medical School at University of Texas Health Science Center at Houston, Houston, Texas; 6Division of Pediatric Nephrology, Department of Pediatrics, Children’s Mercy Kansas City, Kansas City, Missouri; 7Division of Pediatric Nephrology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; 8Division of Nephrology, University of California San Francisco, San Francisco, California; 9Department of Internal Medicine, University of California San Francisco, San Francisco, California; and 10Division of Nephrology and Hypertension, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio